Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: The tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy study

C. Genovese, Mark; D. McKay, James; Л. Насонов, Е.; Mysler, Eduardo; A Da Silva, Nilzio; Alecock, Emma; Woodworth, Thasia; J. Gómez‐Reino, Juan

doi:10.1002/art.23940

Public

Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: The tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy study

Published in Arthritis & Rheumatism • Sep 29, 2008

Authors:

Mark C. Genovese

James D. McKay

Е. Л. Насонов

Abstract

OBJECTIVE: To examine the efficacy and safety of the humanized anti-interleukin-6 receptor antibody tocilizumab combined with conventional disease-modifying antirheumatic drugs (DMARDs) in patients with active rheumatoid arthritis (RA). METHODS: A total of 1,220 patients were randomized (2:1 ratio) ...

Subject

Tocilizumab

Medicine

Rheumatoid arthritis

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!